CDK4 and breast cancer: Furthermore, enforced expression of miR-126-3p in drug treatment-naive non-small cell lung cancer cells [42], renal cancer cells [60] or breast cancer cells [61] has been shown to increase sensitivity to vincristine and adriamycin, cisplatin, and CDK4/6 or PIK3CA inhibitors, respectively.